Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology firm specializing in integrin-based therapeutics, is set to participate in the Piper Sandler 37th Annual Healthcare Conference from December 2 to 4, 2025. Key executives, including President and CEO Dr. Bernard Coulie, CFO Dr. Keith Cummings, and Chief Medical Officer Dr. Éric Lefebvre, will take part in a fireside chat scheduled for December 4 at 12:30 p.m. Eastern Time. Interested audiences can access a live webcast of the discussion through the Investor Relations section on Pliant’s website, with an archived replay available for 90 days post-event.

Pliant Therapeutics focuses on the discovery and development of cutting-edge therapies targeting integrin receptors, which play a critical role in various disease processes. The company's lead candidate, PLN-101095, is a dual-selective small molecule inhibitor aimed at treating solid tumors by targeting specific integrins, namely ?v?8 and ?v?1. Additionally, Pliant is progressing with PLN-101325, a monoclonal antibody agonist for integrin ?7?1, designed for use in treating muscular dystrophies, and has already secured regulatory approval to initiate a Phase 1 clinical trial for this compound.

The company’s innovative early-stage platform is enhancing research into the tissue-specific delivery of therapeutic agents, leveraging integrin receptor-binding technologies to improve drug efficacy and safety. Investors and interested parties can follow Pliant on various social media platforms, including X, LinkedIn, and Facebook. For further details regarding their pipeline and corporate initiatives, visit Pliant's official website at www.PliantRx.com.

Pliant Therapeutics, Inc. (Nasdaq: PLRX) is making waves as it prepares to present at the Piper Sandler Healthcare Conference from December 2-4, 2025. With its focus on integrin-based therapeutics and promising lead programs, including PLN-101095 and PLN-101325, the company presents an interesting investment opportunity for those willing to delve into the biotech sector.

As a clinical-stage biotechnology company, Pliant is in a crucial development phase that can lead to significant market appreciation. PLN-101095, aimed at treating solid tumors, addresses a critical need in oncology, while PLN-101325’s potential application in muscular dystrophies expands the company’s reach. These key therapeutic targets are strategically aligned with high unmet medical needs, which can attract partnerships and increase investor interest.

Investors should keenly observe the strategic insights shared during the upcoming fireside chat featuring CEO Bernard Coulie and other executives. Such platforms not only provide an opportunity to acquire deeper knowledge about the company’s pipeline but can also influence stock performance based on investor sentiment and perceived growth prospects.

In the current volatile biotech landscape, investors should consider Pliant as a long-term play, especially if the upcoming regulatory developments and trial results remain positive. The upcoming Phase 1 study for PLN-101325 could serve as a catalyst, potentially driving share prices higher if the results align with investor expectations.

For those looking to establish a position in Pliant Therapeutics, it may be wise to monitor the stock closely post-conference for any shifts in market sentiment. With its solid therapeutic focus and an active developmental pipeline, Pliant Therapeutics warrants a spot on the radar of investors seeking growth in the biopharmaceutical sector.